Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 189,613 shares of the biotechnology company's stock after acquiring an additional 36,875 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.31% of Ascendis Pharma A/S worth $28,713,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth about $28,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares in the last quarter. Quarry LP bought a new stake in Ascendis Pharma A/S in the 4th quarter worth approximately $96,000. Tower Research Capital LLC TRC raised its holdings in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $174,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ASND. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Bank of America lifted their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research report on Friday, May 2nd. Oppenheimer reissued an "outperform" rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $220.67.

Ascendis Pharma A/S Trading Up 0.6%

Shares of NASDAQ ASND traded up $0.97 during midday trading on Friday, reaching $174.07. The company had a trading volume of 157,816 shares, compared to its average volume of 500,084. The stock has a market cap of $10.64 billion, a P/E ratio of -27.72 and a beta of 0.38. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The business's 50-day simple moving average is $167.48 and its 200 day simple moving average is $151.91.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.